Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ingested interferon-alpha prevents allograft islet transplant rejection.

S A Brod1, S Katz, T Phan

  • 1Department of Neurology, University of Texas-Houston, Health Science Center, 77225, USA. sbrod@neuro.med.uth.tmc.edu

Transplantation
|June 14, 2000
PubMed
Summary

Ingested interferon-alpha (IFN-alpha) delayed islet allograft rejection in diabetic mice. Continuous administration of IFN-alpha may prevent rejection in some cases, offering a potential therapeutic strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variable results after rituximab in neuromyelitis optica.

Journal of the neurological sciences·2012
Same author

Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research·2002
Same author

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

Neurology·2001
Same author

Unregulated inflammation shortens human functional longevity.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2000
Same author

Adoptive transfer from interferon-alpha-fed mice is associated with inhibition of active experimental autoimmune encephalomyelitis by decreasing recipient tumor necrosis factor-alpha secretion.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2000
Same author

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis.

Annals of neurology·2000

Area of Science:

  • Immunology
  • Transplantation immunology
  • Endocrinology

Background:

  • Interferon-alpha (IFN-alpha) acts as a biological response modifier.
  • Islet transplantation is a promising alternative to exogenous insulin therapy for diabetes.
  • Preventing islet allograft rejection is crucial for successful transplantation.

Purpose of the Study:

  • To investigate the efficacy of ingested interferon-alpha (IFN-alpha) in preventing islet allograft rejection.
  • To determine if IFN-alpha administration can prolong the survival of transplanted islets.

Main Methods:

  • Diabetic C3H mice received islet allografts from C57BL.10 donors.
  • Mice were treated with varying doses of ingested murine IFN-alpha daily for 21 to 42 days.
  • Graft rejection was monitored by observing blood glucose levels.

Related Experiment Videos

Main Results:

  • Ingested IFN-alpha significantly delayed islet allograft rejection in a dose-dependent manner.
  • Treatment with 10-100 IU of IFN-alpha extended the time to rejection by up to 29 days compared to controls.
  • Continuous administration of IFN-alpha for 42 days showed a greater delay in rejection.

Conclusions:

  • Prolonged administration of ingested IFN-alpha can prevent islet allograft rejection in a subset of recipients.
  • Continuous IFN-alpha treatment post-transplantation holds potential for improving islet allograft survival.
  • Ingested IFN-alpha represents a potential therapeutic approach for managing islet transplantation outcomes.